ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505054-17-00

Acronym

ANTELOPE

Enrollment

136

Registered

2023-07-14

Start date

2023-09-15

Completion date

Unknown

Last updated

2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic TTF-1 negative lung adenocarcinoma

Brief summary

Overall survival (OS)

Interventions

DRUGCARBOPLATIN

DRUGCISPLATIN

DRUGPEMBROLIZUMAB

DRUGPACLITAXEL ALBUMIN-BOUND

DRUGPEMETREXED

DRUGATEZOLIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival (OS)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026